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ABSTRACT
Objectives: Preeclampsia (PE) is a pregnancy complication caused by typically limited proliferation, apoptosis, migration, 
and invasion of extra-trophoblast cells. Decorin (DCN) is a decidua-derived transforming growth factor (TGF)-binding 
proteoglycan which exerts multiple physiological functions such as collagen fibrillogenesis, myogenesis, angiostasis, and 
restraining placental invasiveness by adversely regulate proliferation, migration, and invasiveness of human extravillous 
trophoblast cells. Preeclampsia is mainly classified as early- and late-onset PE according to the timing of the disease onset. 
In the present study, we aimed to investigate the DCN levels in early-onset PE (EOPE, < 34 weeks) and late-onset severe PE 
(LOPE, ≥ 34 weeks) and uncomplicated pregnancies.
Material and methods: In this case-control study, serum samples were obtained from 21 pregnant women with EOPE 
and 29 pregnant women with LOPE, as well as from 38 healthy controls (n = 12 early-onset controls and n = 26 late-onset 
controls) with uncomplicated pregnancies.
Results: The mean DCN level was statistically significantly higher in the early-onset PE controls than late-onset PE controls 
(p = 0.040). Although the mean DCN level was higher in the early-onset PE controls than EOPE and LOPE groups, it did not 
reach statistical significance (p = 0.119 and p = 0.117, respectively). 
Conclusions: Although DCN has been thought to play a role in the pathophysiology of PE, our study results show that DCN 
is not a useful predictive marker of EOPE and LOPE. Further large-scale studies are needed to draw a definitive conclusion. 
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INTRODUCTION
Hypertensive disorders in pregnancy are a major health 
problem worldwide and preeclampsia (PE) is the most com-
mon complication [1]. Preeclampsia accounts for 3 to 5% 
of all pregnancies and is one of the leading causes of ma-
ternal, fetal, and neonatal mortality and morbidity [2]. It is 
mainly classified as early-onset (< 34 weeks) and late-onset 
(≥ 34 weeks) [3]. Although initial symptoms are similar in 
both conditions, they have unique biomarkers, genetic risk 
factors, prognosis, and clinical characteristics [4].
Decorin (DCN), an extracellular matrix protein, is 
a small leucine-rich proteoglycan expressed in connective 
tissue. It contains a protein core and a single chondroi-
tin/dermatan sulfateglycosaminoglycan chain bound at 
the N-terminal extension. Previous studies have shown that 
DCN plays a role in the cell proliferation and formation of 
collagen fibers and modulates certain cell functions (i.e., 
proliferation, dissemination, migration, and differentiation) 
acting as a critical modulator of inflammation. In addition, 
DCN is a molecule which is highly expressed in reproduc-
tive tissues [5–7]. 
Decorin binds to the transforming growth factor-beta 
(TGF-β) and activates signaling pathways. The TGF-β binds to 
its own receptor and induces phosphorylation of the Smad 
family, which is one of the transcription factors, thereby, 
modulating the transcription of collagen, matrix metallopro-
teinases (MMPs), and metalloproteinase tissue inhibitors [8]. 
Irrespective of these mechanisms, DCN stimulates phospho-
rylation of vascular endothelial growth factor (VEGF) and 
insulin-like growth (IGF) receptor expressed by extra-villous 
trophoblasts [9].
In the literature, alterations in the DCN levels have been 
shown to be associated with PE. In a study, Gogiel et al. [10] 
reported increased DCN levels of the umbilical cord vein wall 
in patients with PE. Similarly, Siddiqui et al. [11] found that 
increased DCN levels were predictors of PE even before the 
onset of clinical symptoms. The link between DCN and PE 
can be attributed to the impaired proliferation and migra-
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tion of trophoblasts and endothelial dysfunction, which are 
thought to be responsible for adverse pregnancy outcomes 
(APOs). On the other hand, there is a limited number of 
studies showing the relationship between DCN and APOs 
with controversial results.
Based on the pathophysiological mechanisms of PE, we 
hypothesized that DCN would be useful in the diagnosis of 
PE, particularly in early-onset PE. In the present study, we, 
therefore, aimed to investigate the DCN levels in early-onset 
PE (EOPE) and late-onset PE (LOPE) and uncomplicated 
pregnancies.
MATERIAL AND METHODS
This prospective, case-control study was carried out at 
Bursa Yüksek Ihtisas Training and Research Hospital, Obstet-
rics and Gynecology outpatient clinics between January 
2019 and March 2019. A total of 88 participants aged between 
18 and 35 years (n = 50 PE and n = 38 healthy controls) were 
included in the study. The patient group was classified as 
EOPE (n = 21) and LOPE (n = 29). The control group consisted 
of healthy women with singleton pregnancy with similar ges-
tational weeks who were under follow-up in our outpatient 
clinics with uncomplicated pregnancies. Patients with chronic 
hypertension, thyroid dysfunction, renal or cardiovascular dis-
ease, and multiple pregnancy were excluded from the study. 
Of the control group, 12 were in the < 34th week of pregnancy 
(early-onset PE controls) and 26 were in the ≥ 34th week of 
pregnancy (late-onset PE controls). A written informed con-
sent was obtained from each participant. The study protocol 
was approved by the institutional Ethics Committee (2011- 
-KAEK-25 2019/02-10). The study was conducted in accord-
ance with the principles of the Declaration of Helsinki.
Data including demographic data of the patients, ma-
ternal age, parity/gravida, last menstrual period, gestational 
age, body weight and height, and systolic and diastolic 
blood pressure were recorded. In those with unknown last 
menstrual period, the gestational age was calculated based 
on the crown-rump length as assessed by ultrasound in the 
first trimester.
The diagnosis of PE was based on a systolic blood pres-
sure of ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, 
measured twice in 4 to 6-hour intervals while resting, after 
the 20th gestational week accompanied by 300 mg/dL pro-
teinuria in a 24-hour urine sample, or more than +1 protein-
uria in spot urine specimens. Early-onset PE was defined as 
the onset before 34 weeks of pregnancy, while late-onset PE 
was defined as the onset after 34 weeks of pregnancy. The 
presence of intrauterine growth retardation (IUGR) defined 
as an estimated fetal weight below the 10th percentile for 
the gestational age birth.
All patients were followed during pregnancy. Data includ-
ing birth data, birth weight, and type of labor were recorded. 
Biochemical Analyses
A 5-mL venous blood sample was drawn from each pa-
tient during their ward stay and from each healthy control 
during outpatient visit. The samples were centrifuged at 
3,500 rpm for 10 min and kept at –80º until analysis. Serum 
DCN levels were analyzed using the enzyme-linked immu-
nosorbent (ELISA) method.
Complete blood count and biochemical parameters 
were analyzed. Complete blood count was analyzed us-
ing the Roche SYSMEX analyzer (Roche Diagnostics, Basel, 
Switzerland). In addition, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), lactate dehydrogenase 
(LDH), total bilirubin, hemoglobin, creatinine, uric acid, and 
urinalysis were examined using the Synchron LX20 system 
(Beckman Coulter Diagnostics, CA, USA).
Statistical Analysis
Statistical analysis was performed using the SPSS version 
23.0 software (IBM Corp., Armonk, NY, USA). Descriptive data 
were expressed in mean ± standard deviation (SD), quartile 
(25th, 50th, and 75th), and number and frequency. The Kol-
mogorov-Smirnov test was used to test normal distribution of 
continuous variables. The Kruskal-Wallis test was used to ana-
lyze significant differences between non-normally distributed 
variables. The post-hoc Dunn test was performed to identify 
groups with significant differences. The Fisher-Freeman-Halton 
exact test was used to examine distribution of categorical vari-
ables. The Spearman’s correlation analysis was carried out to 
examine the relationship between DCN levels and other vari-
ables. A p value of < 0.05 was considered statistically significant.
RESULTS
A total of 88 participants including 50 patients with PE 
and 38 healthy controls were included in this study. Of the 
patients, 21 had EOPE and 29 had LOPE. Of the healthy con-
trols, 12 were early-onset PE controls and 26 were late-onset 
PE controls. Demographic and clinical characteristics and 
biochemical analyses are shown in Table 1.
Although the mean body weight (p = 0.001), body mass 
index (p = 0.006), systolic (p = 0.001) and diastolic blood 
pressure (p = 0.001), ALT (p = 0.001), hemoglobin(p = 0.016), 
and creatinine (p = 0.001) levels did not significantly differ 
between the either control group, these levels were sig-
nificantly lower in the control groups than EOPE and LOPE 
groups. The mean AST level was similar between the control 
groups and in the LOPE group, but was significantly lower 
than the EOPE group (p = 0.001). On the other hand, there 
was no significant difference in the platelet counts between 
the control groups; however, the mean platelet count was 
significantly higher than the EOPE and LOPE groups. In ad-
dition, the mean platelet count was significantly lower in 
the EOPE group than the LOPE group (p = 0.001)
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Table 1. Demographic and clinical characteristics and biochemical analyses
EOPE LOPE Late-onset PE controls Early-onset PE controls p
Age, [year]
N 21 29 26 12
0.082
Mean 29.76 30.72 26.62 26.42
SD 7.293 6.403 6.682 6.735
Percentiles
25th 23.50 25.50 21.75 22.00
Median 29.00 32.00 25.00 23.50
75th 37.00 36.00 31.00 32.00
Weight, [kg]
N 21 29 26 12
0.001
Mean 90.48a 76.73b 70.58b
SD 20.373 10.452 11.889
Percentiles
25th 76.00 74.00 69.50 61.50
Median 80.00 90.00 79.00 68.00
75th 87.50 101.00 85.00 79.50
Height, [cm]
N 21 29 26 12
0.302
Mean 163.41 162.88 159.25
SD 5.172 6.755 6.930
Percentiles
25th 159.00 160.00 159.50 154.00
Median 162.00 165.00 164.00 160.00
75th 166.00 166.50 167.25 165.00
BMI, [kg/m2]
N 21 29 26 12
0.006
Mean 31.8625a 33.9284a 28.9815b 27.8364b
SD 5.55135 7.76778 4.10810 4.43420
Percentiles
25th 29.1279 28.3595 26.7589 24.2936
Median 31.6337 34.8944 28.3356 26.1656
75th 34.4410 37.5954 32.0019 32.3027
SBP, mmHg
N 21 29 26 12
0.001
Mean 162.86a 157.59a 110.00b 110.00b
SD 18.205 19.208 10.583 8.528
Percentiles
25th 150.00 150.00 100.00 100.00
Median 160.00 150.00 110.00 110.00
75th 175.00 165.00 120.00 120.00
DBP, mmHg
N 21 29 26 12
0.001
Mean 104.76a 98.97b 65.77c 66.67c
SD 8.136 10.805 7.575 8.876
Percentiles
25th 100.00 90.00 60.00 60.00
Median 100.00 100.00 70.00 70.00
75th 110.00 100.00 70.00 70.00
Gravida
N 21 29 26 12
0.876
Mean 2.43 2.72 2.23 2.33
SD 1.720 1.771 0.863 1.073
Percentiles
25th 1.00 1.00 2.00 1.00
Median 2.00 2.00 2.00 3.00
75th 3.00 4.00 3.00 3.00
Parity
N 21 29 26 11
0.788
Mean 1.10 1.10 1.15 1.36
SD 1.221 1.263 0.881 1.206
Percentiles
25th 0.00 0.00 0.75 0.00
Median 1.00 1.00 1.00 2.00
75th 2.00 2.00 2.00 2.00

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Table 1. Demographic and clinical characteristics and biochemical analyses (continued)
EOPE LOPE Late-onset PE controls Early-onset PE controls p
Abortus
N 21 29 26 12
0.057
Mean 0.33 0.62 0.08 0
SD 0.796 1.115 .272 0
Percentiles
25th 0 0 0 0
Median 0 0 0 0
75th 0 1.00 0 0
Live birth
N 21 29 26 12
0.635
Mean 1.10 1.10 1.15 1.50
SD 1.221 1.263 0.881 1.243
Percentiles
25th 0 0 0.75 0
Median 1.00 1.00 1.00 2.00
75th 2.00 2.00 2.00 2.75
PLT, [103/mL]
N 21 29 26 12
0.001
Mean 109.52a 146.93b 264.73c 272.00c
SD 42.666 63.837 62.332 38.657
Percentiles
25th 83.50 98.50 197.00 248.25
Median 96.00 140.00 275.00 263.00
75th 148.00 181.00 313.00 282.50
WBC, [103/mL]
N 21 29 25 12
0.021
Mean 15.457a 14.345a 12.992ab 10.950b
SD 5.6085 4.0497 3.4938 1.5193
Percentiles
25th 10.800 11.200 10.350 9.525
Median 17.800 13.500 12.100 11.200
75th 19.650 17.750 16.350 11.600
Hb, [g/dL]
N 21 29 26 12
0.016
Mean 10.6000a 10.6586a 11.5769b 11.5250b
SD 1.44948 1.18609 1.18061 1.25200
Percentiles
25th 9.6000 9.8000 10.9000 10.4250
Median 10.9000 10.9000 11.8000 11.3000
75th 11.6000 11.5500 12.5000 12.6000
AST, [IU/L]
N 21 29 26 12
0.001
Mean 115.7619a 61.3448b 20.2308b 19.4167b
SD 66.05067 40.55972 8.18441 4.01040
Percentiles
25th 50.0000 27.5000 13.5000 16.2500
Median 121.0000 46.0000 18.5000 19.0000
75th 152.0000 93.5000 25.0000 22.0000
ALT, [U/L]
N 21 29 26 12
0.001
Mean 111.3810a 53.3207b 16.2692c 12.6667c
SD 76.59209 48.74625 9.15885 3.65148
Percentiles
25th 26.0000 21.0000 9.7500 10.2500
Median 117.0000 35.0000 13.5000 12.0000
75th 154.0000 70.0000 23.0000 15.7500
Urea, [mg/dL]
N 21 29 26 12
0.001
Mean 20.8095a 15.3310b 8.6231c 6.4333d
SD 6.87836 5.97764 2.37627 2.45872
Percentiles
25th 14.7000 10.7000 7.1750 4.6000
Median 21.7000 15.0000 8.4500 6.1000
75th 25.7000 18.3000 10.0500 8.0000
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The mean DCN level was statistically significantly higher 
in the early-onset PE controls than late-onset PE controls 
(p = 0.040). Although the mean DCN level was higher in the 
early-onset PE controls than the EOPE and LOPE groups, it 
did not reach statistical significance (p = 0.119 and p = 0.117, 
respectively). However, based on the p values of these vari-
ables, the difference between the groups may be of biologi-
cal relevance, although not statistically significant.
DISCUSSION
Preeclampsia is one of the complications of pregnancy 
and is mainly classified into two types according to the time 
of occurrence: early-onset PE (< 34th week of pregnancy) 
and late-onset PE (≥ 34th week of pregnancy). 'Early-onset 
PE occurs in about 10% of all preeclamptic cases and has 
a complex pathophysiology, the main cause being abnor-
mal placentation with maternal predictive factors. It seems, 
therefore, reasonable to gain a better understanding of the 
underlying angiogenic imbalance in early- and late-onset 
PE and to identify and treat candidate patients at the end 
of the first trimester, as the incidence of maternal vascular 
malperfusion and placental vascular lesions are higher in 
early-onset PE [12]. 
Failed trophoblast invasion has been proposed the main 
pathogenetic mechanism in PE. Previous studies have dem-
onstrated that PE is a two-stage disorder: abnormal placen-
tation with reduced placental perfusion in the first stage 
and maternal systemic pathophysiological changes in the 
second stage. However, the exact underlying mechanism of 
the lack of invasion of extravillous trophoblasts in PE remains 
to be elucidated [13].
Implantation and placentation are essential compo-
nents of pregnancy which thoroughly rely upon funda-
mental biological processes invasive trophoblasts, growth 
factors, growth factor binding proteins, proinflammatory 
cytokines, proteoglycans, and including highly MMPs. The 
regulation of MMP activity is the mainstay of these critical 
processes. Dysregulation of these delicate processes may 
result in a broad range of pregnancy abnormalities such as 
PE, IUGR, preterm labor, and miscarriage [14].
Table 1. Demographic and clinical characteristics and biochemical analyses
EOPE LOPE Late-onset PE controls Early-onset PE controls p
Creatinine, 
[mg/dL]
N 21 29 26 12
0.001
Mean 1.0648a .9500a .6688b .6558b
SD .33898 .31988 .14605 .10757
Percentiles
25th 0.7450 0.7100 0.5950 0.6025
Median 1.1000 0.8300 0.6300 0.6750
75th 1.2650 1.2000 0.7000 0.7175
Gestational week
N 21 29 26 12
0.001
Mean 30.48a 35.90b 37.12c 37.42c
SD 2.462 1.566 1.532 2.065
Percentiles
25th 28.50 35.00 36.00 37.00
Median 32.00 36.00 37.00 38.00
75th 32.00 37.00 38.25 39.00
Birth weight, [g]
N 20 29 26 12
0.001
Mean 1239.25a 2572.45b 3044.23c 3003.33c
SD 475.448 722.840 581.914 622.405
Percentiles
25th 847.50 1965.00 2460.00 2912.50
Median 1215.00 2530.00 3160.00 3150.00
75th 1527.50 3275.00 3490.00 3350.00
Decorin, [pg/mL]
N 21 29 26 12
0.040
Mean 10.8524 11.0276 9.9750 14.4250
SD 4.34714 3.86577 4.56240 5.24632
Percentiles
25th 7.4000 8.4500 8.0000 10.8250
Median 10.2000 9.5000 10.1000 13.8000
75th 15.0000 13.8000 11.8750 19.5000
EOPE — early-onset preeclampsia; LOPE— late-onset preeclampsia; PE— preeclampsia; SD— standard deviation; BMI— body mass index; SBP— systolic blood 
pressure; DBP— diastolic blood pressure; PLT— platelet; WBC— white blood cell; Hb— hemoglobin; AST— aspartate aminotransferase; ALT— alanine aminotransferase
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In the early period of pregnancy, the fetoplacental 
development is mediated by a complex cascade system 
containing growth factors, cytokines, and transcription 
factors [15]. Decorin is a product of both fetal mesenchymal 
cells within the placenta and decidual cells in the endo-
metrium. Currently, the role of DCN in stem cell regulation 
and in the underlying pathogenesis of PE and IUGR has 
not been fully elucidated. During a recent study, Siddiqui 
et al. [11] investigated the relation of DCN overexpression 
in the chorionic villi and/or basal decidua with PE. They 
reported that basal decidual cell-induced DCN overexpres-
sion was related to hypoinvasive phenotype with poor 
endovascular trophoblast cell differentiation in PE. In ad-
dition, the authors found no significant change in DCN 
levels depending on gestational age during the second 
trimester in PE patients, although there was an inverse as-
sociation between the plasma DCN levels and body mass 
index or body weight. Based on these findings, the au-
thors concluded that increased plasma DCN level might 
be a predictor of PE before the onset of clinical signs. In 
another study, Siddiqui et al. [11] found that DCN messen-
ger ribonucleic acid (mRNA) expression at the cellular level 
showed significantly increased expression in basal plate 
decidual cells within the placentas from PE (23 to 40 weeks 
of gestation) patients than controls at all gestational age. 
Similarly, Nandi et al. [16] found a significant difference in 
the DCN staining of placental tissues between the PE and 
control groups. However, at the tissue level, DCN mRNA 
expression in chorionic villi was similar. In another study, 
Nandi et al. [17] reported that elevated DCN levels in the 
maternal blood could be a predictive biomarker for PE.
For a healthy pregnancy, the maternal blood vessel re-
modeling is driven by the extravillous cytotrophoblasts 
rather than maternal endothelium. Reduced interstitial inva-
sion and endovascular cytotrophoblasts are associated with 
IUGR. In their study, Weber et al. [18] described a variety of 
trophoblast  stem cell and pluripotency marker staining 
patterns based on gestational age and placenta-associat-
ed pregnancy complications. The authors concluded that 
PE, IUGR, and combined PE + IUGR are separate entities 
based on the differential expression patterns within the 
placentas complicated with placenta-associated pregnancy 
complications. We believe that reduced DCN may lead to 
uncontrolled proliferation and inadequate differentiation 
of cytotrophoblasts, thereby, resulting in impaired ion-nu-
trition exchange and decreased hormonal synthesis. More 
importantly, differentiation of cytotrophoblasts is the cor-
nerstone of healthy placental development in human [15]. 
In a study, Tan et al. [19] found that abnormal differentia-
tion of trophoblast stem cells was likely to be associated with 
IUGR. Since certain types of IUGR and PE share a common 
placental pathology, the authors concluded that overexpres-
sion of DCN in the placenta/decidua led to poor trophoblast 
differentiation in an IUGR subgroup. 
Caglar et al. [20] compared DCN levels between preg-
nancies complicated by idiopathic IUGR and uncomplicated 
pregnancies and examined the possible relationship be-
tween DCN levels and clinical parameters. They found sig-
nificantly higher maternal serum DCN levels in complicated 
pregnancies by IUGR and an about 8-times higher risk of 
high maternal serum DCN levels in complicated pregnancies. 
In a study, Murthi et al. [21] collected first trimester 
tissues via chorionic villus sampling and investigated the 
temporal relationship between subsequent development 
of small for gestational age (SGA) and altered DCN expres-
sion. The DCN mRNA were determined via using real-time 
polymerase chain reaction (PCR) and DCN proteins via im-
munoblotting. The authors showed that DCN mRNA and 
protein significantly decreased in the placentas from the 
first-trimester SGA-pregnancies. The aforementioned study 
is to the first to report a temporal relationship between sub-
sequent development of SGA and altered placental DCN ex-
pression in the literature. Similarly, in a previous study of the 
same researchers, the DCN expression significantly reduced 
in IUGR compared to gestation-matched controls [22].
The mean DCN level was statistically significantly higher 
in the early-onset PE controls than late-onset PE controls 
(p = 0.040). Although the mean DCN level was higher in the 
early-onset PE controls than EOPE and LOPE groups, it did not 
reach statistical significance (p = 0.119 and p = 0.117, respec-
tively). However, based on the p values of these variables, we 
suggest that the difference between the groups may be of 
biological relevance, although not statistically significant.
Nonetheless, there are some limitations to this study. 
First, due to the prospective design of the study and ter-
mination of the data cut-off date, the number of patients 
in the control group cannot be increased. Second, we were 
unable to perform immunohistochemical staining for DCN 
expression of placental tissues. Despite the lack of any sta-
tistically significant difference in the maternal serum DCN 
samples between the early-onset and late-onset PE groups, 
no data are available whether there is a significant differ-
ence in the DCN level of placental tissues due to the lack of 
immunohistochemical stating.
In conclusion, although DCN has been thought to be in-
volved in the pathophysiology of PE, our study results show 
that DCN is not a useful predictive marker of EOPE and LOPE. 
However, these results might have been yielded due to small 
sample size of our study. Therefore, further large-scale stud-
ies are needed to draw a definitive conclusion. Furthermore, 
it would be more helpful to gain an insight into the role of 
DCN in the pathophysiology of PE by measuring the DCN 
mRNA expression in the basal plate decidual cells within the 
placenta with immunohistochemical staining.
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